AlphaTON Capital Signs Acquisition Agreement with Immunova

AlphaTON Capital announced the execution of a binding call option agreement with Immunova, granting Immunova, or an affiliate, the option to acquire iOx Therapeutics Limited, a wholly owned subsidiary of AlphaTON focused on developing liposomal iNKT agonists. Upon exercise of the option and completion of the acquisition, AlphaTON would be entitled to an upfront cash payment at closing, equity consideration representing 10% of the fully diluted equity of the acquiring entity at the time of exercise, milestone payments potentially exceeding $100M, payable upon achievement of specified milestones, and single-digit royalties on future net sales, subject to the terms of the definitive documentation. "Executing this agreement is an important step to unlock value from iOx while preserving meaningful long-term economic participation for AlphaTON," said Brittany Kaiser, Chief Executive Officer of AlphaTON Capital. "iOx is a differentiated, clinically supported lipid-based immune program, and placing it with Immunova enables dedicated execution under a focused development platform. We will continue to advance our mesothelioma program, where we remain on track to dose the first patient with TT-4, and we are progressing our new Telegram-oriented, AI-driven biotech initiative aimed at rare cancers. This is about maximizing value across the portfolio with clear priorities and disciplined execution."